

Sofia Ramiro

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6654212/sofia-ramiro-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

431
papers

49,034
citations

90
h-index

219
g-index

519
ext. papers

60,064
ext. citations

4.5
avg, IF

7.51
L-index

#	Paper	IF	Citations
431	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2569-81		4825
430	Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. <i>New England Journal of Medicine</i> , 2000 , 343, 1594-602	59.2	2590
429	2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1580-8	2.4	2158
428	Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. <i>Lancet, The</i> , 1999 , 354, 1932-9	40	1960
427	Rheumatoid arthritis. <i>Lancet, The</i> , 2016 , 388, 2023-2038	40	1794
426	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 960-977	2.4	1649
425	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 492-509	2.4	1487
424	Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1998 , 41, 1552-63		1357
423	Treating rheumatoid arthritis to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 631-7	2.4	1300
422	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 964-75	2.4	1210
421	Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. <i>Lancet, The</i> , 2008 , 371, 987-97	40	1101
420	Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. <i>Arthritis and Rheumatism</i> , 2004 , 50, 3432-43		948
419	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 685-699	2.4	851
418	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 3-15	2.4	814
417	2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 978-991	2.4	801
416	Rheumatoid arthritis. <i>Nature Reviews Disease Primers</i> , 2018 , 4, 18001	51.1	750
415	New therapies for treatment of rheumatoid arthritis. <i>Lancet, The</i> , 2007 , 370, 1861-74	40	706

414	Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. <i>Arthritis Research</i> , 2005 , 7, R796-806		640
413	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 736-745	2.4	628
412	European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 499-510	2.4	611
411	Diagnosis and Management of Rheumatoid Arthritis: A Review. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 1360-1372	27.4	596
410	American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Arthritis and Rheumatism</i> , 2011 , 63, 573-86		520
409	American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 404-13	2.4	518
408	EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 34-45	2.4	508
407	Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 62-8	2.4	467
406	Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. <i>Lancet, The</i> , 2009 , 374, 210-21	4.0	416
405	EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 636-643	2.4	401
404	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 958-67	2.4	388
403	EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 804-14	2.4	376
402	The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2005 , 23, S100-8	2.2	375
401	Baricitinib in Patients with Refractory Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2016 , 374, 1243-52	59.2	365
400	Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. <i>Arthritis and Rheumatism</i> , 2005 , 52, 2625-36		337
399	Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. <i>Arthritis and Rheumatism</i> , 2006 , 54, 702-10		336
398	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 3-17	2.4	320
397	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 6-16	2.4	308

396	Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 909-20	2.4	308
395	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 529-35	2.4	266
394	Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. <i>Nature Reviews Rheumatology</i> , 2015 , 11, 276-89	8.1	265
393	2016 update of the EULAR recommendations for the management of early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 948-959	2.4	243
392	EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 700-712	2.4	238
391	Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. <i>Lancet, The</i> , 2017 , 390, 457-468	4.0	227
390	Inequities in access to biologic and synthetic DMARDs across 46 European countries. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 198-206	2.4	225
389	Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 516-28	2.4	224
388	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1101-1136	2.4	213
387	Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. <i>Arthritis and Rheumatism</i> , 2006 , 54, 2784-92		205
386	Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 811-8	2.4	202
385	A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 319-26	2.4	201
384	A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1012-9	2.4	200
383	Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. <i>Lancet, The</i> , 2014 , 383, 321-32	4.0	196
382	Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1455-61	2.4	190
381	Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1441-7	2.4	182
380	Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. <i>Arthritis and Rheumatism</i> , 2007 , 56, 3226-35		181
379	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 554-561	2.4	175

378	A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. <i>Rheumatology</i> , 2009 , 48, 1114-21	3.9	173
377	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 638-643	2.4	168
376	Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 64-71	2.4	161
375	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 16-22	2.4	156
374	Proposal for a new nomenclature of disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 3-5	2.4	155
373	Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment. <i>Journal of Rheumatology</i> , 2019 , 46, 7-18	4.1	150
372	Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1113-1136	2.4	143
371	Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. <i>Lancet, The</i> , 2019 , 393, 2303-2311	4.0	143
370	2018 update of the EULAR recommendations for the management of hand osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 16-24	2.4	142
369	Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1143-1151	2.4	137
368	The role of biosimilars in the treatment of rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 322-8	2.4	134
367	EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 851-858	2.4	133
366	Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 52-9	2.4	127
365	The changing landscape of biosimilars in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 974-82	2.4	124
364	Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1004-9	2.4	121
363	EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. <i>Annals of the Rheumatic Diseases</i> , 2004 , 63, 1172-6	2.4	121
362	Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 165-174	2.4	120
361	The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 495-502	2.4	117

360	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase I. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1589-95	2.4	117
359	Imaging in diagnosis, outcome prediction and monitoring of large vessel vasculitis: a systematic literature review and meta-analysis informing the EULAR recommendations. <i>RMD Open</i> , 2018 , 4, e000612	5.9	116
358	A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 123-131	2.4	116
357	Minimal disease activity for rheumatoid arthritis: a preliminary definition. <i>Journal of Rheumatology</i> , 2005 , 32, 2016-24	4.1	116
356	Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 733-9	2.4	115
355	A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 58-64	2.4	113
354	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 760-770	2.4	112
353	Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. <i>Arthritis and Rheumatism</i> , 2011 , 63, 43-52		110
352	Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 995-1003	2.4	108
351	Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. <i>Lancet, The</i> , 2016 , 388, 2763-2774	4.0	106
350	Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 510-5	2.4	106
349	Development of new syndesmophytes and bridges in ankylosing spondylitis and their predictors: a longitudinal study. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 518-23	2.4	103
348	The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. <i>Best Practice and Research in Clinical Rheumatology</i> , 2007 , 21, 663-75	5.3	100
347	Treating juvenile idiopathic arthritis to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 819-828	2.4	99
346	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72 Suppl 2, ii2-34	2.4	96
345	Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 687-93	2.4	94
344	Prevalence of rheumatic and musculoskeletal diseases and their impact on health-related quality of life, physical function and mental health in Portugal: results from EpiReumaPt- a national health survey. <i>RMD Open</i> , 2016 , 2, e000166	5.9	94
343	A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 831-839	2.4	91

342	Impact of comorbidity on physical function in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 536-41	2.4	90
341	Sacroiliac radiographic progression in recent onset axial spondyloarthritis: the 5-year data of the DESIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1823-1828	2.4	89
340	Comparative effectiveness and safety of biological treatment options after tumour necrosis factor inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1303-8	2.4	88
339	Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 114-23	2.4	87
338	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 482-92	2.4	87
337	The definition and measurement of disease modification in inflammatory rheumatic diseases. <i>Rheumatic Disease Clinics of North America</i> , 2006 , 32, 9-44, vii	2.4	87
336	Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 490-8	2.4	86
335	Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1102-1107	2.4	85
334	Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 234-240	2.4	85
333	Definitions and reliability assessment of elementary ultrasound lesions in giant cell arteritis: a study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group. <i>RMD Open</i> , 2018 , 4, e000598	5.8	85
332	EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 479-81	2.4	85
331	Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. <i>Arthritis Research and Therapy</i> , 2014 , 16, R56	5.7	84
330	Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2011 , 50, 381-8	3.9	81
329	Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1702-5	2.4	81
328	Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1058-64	2.4	79
327	Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 2107-16	2.4	78
326	Marine oil supplements for rheumatoid arthritis. <i>The Cochrane Library</i> , 2012 ,	5.2	78
325	Marine oil supplements for rheumatoid arthritis. <i>The Cochrane Library</i> , 2019 ,	5.2	78

324	Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 744-759	2.4	75
323	The burden of rheumatoid arthritis and access to treatment: uptake of new therapies. <i>European Journal of Health Economics</i> , 2008 , 8 Suppl 2, S61-86	3.6	74
322	Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 534-542	2.4	71
321	Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 2010-21	2.4	71
320	Treat-to-target (T2T) recommendations for gout. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 632-638	2.4	70
319	Development of patient-centred standards of care for rheumatoid arthritis in Europe: the eumusc.net project. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 902-5	2.4	69
318	Ultrasound cut-off values for intima-media thickness of temporal, facial and axillary arteries in giant cell arteritis. <i>Rheumatology</i> , 2017 , 56, 1479-1483	3.9	68
317	Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. <i>RMD Open</i> , 2017 , 3, e000396	5.9	67
316	Superior efficacy of combination therapy for rheumatoid arthritis: fact or fiction?. <i>Arthritis and Rheumatism</i> , 2005 , 52, 2975-83		63
315	The patient perspective on remission in rheumatoid arthritis: 'You've got limits, but you're back to being you again'. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1004-10	2.4	62
314	Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis. <i>RMD Open</i> , 2015 , 1, e000153	5.9	60
313	Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1999-2002	2.4	59
312	Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 546-9	2.4	57
311	Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1190-6	2.4	56
310	Evidence for predictive validity of remission on long-term outcome in rheumatoid arthritis: a systematic review. <i>Arthritis Care and Research</i> , 2010 , 62, 108-17	4.7	56
309	The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?. <i>Arthritis Research and Therapy</i> , 2008 , 10, 208	5.7	56
308	Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 694-700	2.4	55
307	Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 996-1002	2.4	54

306	Criteria for early rheumatoid arthritis: from Bayes' law revisited to new thoughts on pathogenesis. <i>Arthritis and Rheumatism</i> , 2002 , 46, 1155-9		53
305	Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. <i>Nature Reviews Rheumatology</i> , 2016 , 12, 743-750	8.1	52
304	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2018 , 70, 345-355	9.5	51
303	Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. <i>RMD Open</i> , 2017 , 3, e000397	5.9	50
302	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 71-87	2.4	50
301	Gender-attributable differences in outcome of ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study. <i>Rheumatology</i> , 2016 , 55, 419-28	3.9	49
300	Low-dose CT detects more progression of bone formation in comparison to conventional radiography in patients with ankylosing spondylitis: results from the SIAS cohort. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 293-299	2.4	49
299	Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1479-85	2.4	47
298	The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 855-861	2.4	46
297	Lower education and living in countries with lower wealth are associated with higher disease activity in rheumatoid arthritis: results from the multinational COMORA study. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 540-6	2.4	42
296	Determinants of Patient-Physician Discordance in Global Assessment in Psoriatic Arthritis: A Multicenter European Study. <i>Arthritis Care and Research</i> , 2017 , 69, 1606-1611	4.7	41
295	Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 418-421	2.4	40
294	Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS)?. <i>Arthritis Research and Therapy</i> , 2013 , 15, R14	5.7	40
293	Era of biosimilars in rheumatology: reshaping the healthcare environment. <i>RMD Open</i> , 2019 , 5, e000900	5.9	39
292	Development of a multimorbidity index: Impact on quality of life using a rheumatoid arthritis cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2015 , 45, 167-73	5.3	39
291	The importance of reporting disease activity states in rheumatoid arthritis clinical trials. <i>Arthritis and Rheumatism</i> , 2008 , 58, 2622-31		39
290	Cardiovascular morbidity and mortality in ankylosing spondylitis and psoriatic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018 , 32, 369-389	5.3	38
289	Abatacept (CTLA-4Ig) treatment reduces T cell apoptosis and regulatory T cell suppression in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2016 , 55, 710-20	3.9	37

288	Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS. <i>Rheumatology</i> , 2015 , 54, 633-40	3.9	37
287	The need for new classification criteria for rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2005 , 52, 3333-6		37
286	Prevalence and social burden of active chronic low back pain in the adult Portuguese population: results from a national survey. <i>Rheumatology International</i> , 2016 , 36, 183-97	3.6	36
285	In wealthier countries, patients perceive worse impact of the disease although they have lower objectively assessed disease activity: results from the cross-sectional COMORA study. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 715-20	2.4	36
284	Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 171-178	2.4	36
283	Disease activity is longitudinally related to sacroiliac inflammation on MRI in male patients with axial spondyloarthritis: 2-years of the DESIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 874-8	2.4	35
282	Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results. <i>Rheumatology</i> , 2017 , 56, 1771-1779	3.9	35
281	Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 778-786	2.4	35
280	Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 201-208	2.4	35
279	Performance of the ASAS classification criteria for axial and peripheral spondyloarthritis: a systematic literature review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 886-890	2.4	34
278	Risk profiling for a refractory course of rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 49, 211-217	5.3	32
277	Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials. <i>Modern Rheumatology</i> , 2020 , 30, 36-43	3.3	31
276	Implementation of Treat-to-Target in Rheumatoid Arthritis Through a Learning Collaborative: Results of a Randomized Controlled Trial. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1374-1380	9.5	30
275	Reference intervals of spinal mobility measures in normal individuals: the MOBILITY study. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1218-24	2.4	30
274	Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors?. <i>RMD Open</i> , 2015 , 1, e000155	5.9	30
273	Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria. <i>Arthritis and Rheumatology</i> , 2017 , 69, 728-734	9.5	29
272	Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1290-1297	2.4	29
271	Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis. <i>RMD Open</i> , 2019 , 5, e001108	5.9	29

270	Association of Comorbidities in Spondyloarthritis With Poor Function, Work Disability, and Quality of Life: Results From the Assessment of SpondyloArthritis International Society Comorbidities in Spondyloarthritis Study. <i>Arthritis Care and Research</i> , 2018 , 70, 1257-1262	4.7	29
269	Assessing Vasculitis in Giant Cell Arteritis by Ultrasound: Results of OMERACT Patient-based Reliability Exercises. <i>Journal of Rheumatology</i> , 2018 , 45, 1289-1295	4.1	29
268	Patient global assessment in psoriatic arthritis - what does it mean? An analysis of 223 patients from the Psoriatic arthritis impact of disease (PsAID) study. <i>Joint Bone Spine</i> , 2016 , 83, 335-40	2.9	28
267	Interferon signals and monocytic sensitization of the interferon- β signaling pathway in the peripheral blood of patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2012 , 64, 400-8		28
266	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 88-93	2.4	28
265	Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1545-1549	2.4	27
264	Activity assessments in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2008 , 20, 306-13	5.3	27
263	Impact of Chronic Diseases and Multimorbidity on Health and Health Care Costs: The Additional Role of Musculoskeletal Disorders. <i>Arthritis Care and Research</i> , 2016 , 68, 1823-1831	4.7	27
262	Development of the CT Syndesmophyte Score (CTSS) in patients with ankylosing spondylitis: data from the SIAS cohort. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 371-377	2.4	27
261	Disease activity and response assessment in psoriatic arthritis using the Disease Activity index for PSoriatic Arthritis (DAPSA). A brief review. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, S48-50	2.2	27
260	Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Rheumatoid Arthritis (ACR/E). <i>Arthritis Research and Therapy</i> , 2015 , 17, 157	5.7	26
259	Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1810-1818	2.4	26
258	When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS). <i>RMD Open</i> , 2016 , 2, e000221	5.9	26
257	Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1567-70	2.4	25
256	Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis. <i>Lancet Rheumatology</i> , 2020 , 2, e347-e357	14.2	25
255	Work Outcome in Patients With Ankylosing Spondylitis: Results From a 12-Year Followup of an International Study. <i>Arthritis Care and Research</i> , 2016 , 68, 544-52	4.7	25
254	The Minimum Clinically Important Improvement and Patient-acceptable Symptom State in the BASDAI and BASFI for Patients with Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2016 , 43, 1680-6	4.1	25
253	Nonsteroidal Antiinflammatory Drugs for Axial Spondyloarthritis: A Cochrane Review. <i>Journal of Rheumatology</i> , 2016 , 43, 607-17	4.1	23

252	The effects of structural damage on functional disability in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 2038-2045	2.4	23
251	Spinal Radiographic Progression in Early Axial Spondyloarthritis: Five-Year Results From the DESIR Cohort. <i>Arthritis Care and Research</i> , 2019 , 71, 1678-1684	4.7	23
250	Relationship between types of radiographic damage and disability in patients with rheumatoid arthritis in the EURIDISS cohort: a longitudinal study. <i>Rheumatology</i> , 2015 , 54, 83-90	3.9	22
249	Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 453-459	2.4	22
248	Less educated and older patients have reduced access to biologic DMARDs even in a country with highly developed social welfare (Norway): results from Norwegian cohort study NOR-DMARD. <i>Rheumatology</i> , 2016 , 55, 1217-24	3.9	22
247	I Would Never Take Preventive Medication! Perspectives and Information Needs of People Who Underwent Predictive Tests for Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2020 , 72, 360-368	4.7	22
246	What is axial spondyloarthritis? A latent class and transition analysis in the SPACE and DESIR cohorts. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 324-331	2.4	21
245	Back to the future: forget ultrasound and focus on clinical assessment in rheumatoid arthritis management. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 18-20	2.4	21
244	Aspects of validity of the self-administered comorbidity questionnaire in patients with ankylosing spondylitis. <i>Rheumatology</i> , 2014 , 53, 1054-64	3.9	20
243	Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2015 , 17, 203	5.7	20
242	Effect of Comedication With Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Retention of Tumor Necrosis Factor Inhibitors in Patients With Spondyloarthritis: A Prospective Cohort Study. <i>Arthritis and Rheumatology</i> , 2016 , 68, 2671-2679	9.5	20
241	Economic considerations and patients' preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 126-132	2.4	19
240	Patients' experience of shoulder disorders: a systematic review of qualitative studies for the OMERACT Shoulder Core Domain Set. <i>Rheumatology</i> , 2019 ,	3.9	19
239	In rheumatoid arthritis, country of residence has an important influence on fatigue: results from the multinational COMORA study. <i>Rheumatology</i> , 2016 , 55, 735-44	3.9	19
238	Rituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 7-12	2.4	19
237	Response to: 'Comment on: 'EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update' by Gossec ' by Wei. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	19
236	Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1609-1615	2.4	19
235	Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study. <i>RMD Open</i> , 2019 , 5, e000585	5.9	19

234	Are gender-specific approaches needed in diagnosing early axial spondyloarthritis? Data from the SPondyloArthritis Caught Early cohort. <i>Arthritis Research and Therapy</i> , 2018 , 20, 218	5.7	19
233	The Portuguese Society of Rheumatology position paper on the use of biosimilars. <i>Acta Reumatologica Portuguesa</i> , 2014 , 39, 60-71	0.7	19
232	In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response. <i>Arthritis Research and Therapy</i> , 2019 , 21, 28	5.7	18
231	Quality indicators in rheumatoid arthritis: results from the METEOR database. <i>Rheumatology</i> , 2015 , 54, 1630-9	3.9	18
230	Remission in Rheumatoid Arthritis: Working Toward Incorporation of the Patient Perspective at OMERACT 12. <i>Journal of Rheumatology</i> , 2016 , 43, 203-7	4.1	18
229	Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure. <i>Arthritis Research and Therapy</i> , 2006 , 8, R46	5.7	18
228	Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 289-292	2.4	18
227	Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 445-452	2.4	17
226	Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association With Sex in 458 Patients From Fourteen Countries. <i>Arthritis Care and Research</i> , 2020 , 72, 1772-1779	4.7	17
225	Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1268-71	2.4	17
224	Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints?. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1736-1741	2.4	17
223	How are enthesitis, dactylitis and nail involvement measured and reported in recent clinical trials of psoriatic arthritis? A systematic literature review. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 782-783	2.4	16
222	Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1566-1572	2.4	16
221	Is the Site of Back Pain Related to the Location of Magnetic Resonance Imaging Lesions in Patients With Chronic Back Pain? Results From the Spondyloarthritis Caught Early Cohort. <i>Arthritis Care and Research</i> , 2017 , 69, 717-723	4.7	16
220	The burden of rheumatoid arthritis and access to treatment: a medical overview. <i>European Journal of Health Economics</i> , 2008 , 8 Suppl 2, S39-47	3.6	16
219	Socioeconomic inequities in perceived health among patients with musculoskeletal disorders compared with other chronic disorders: results from a cross-sectional Dutch study. <i>RMD Open</i> , 2015 , 1, e000045	5.9	15
218	Outcomes assessed in trials of gout and accordance with OMERACT-proposed domains: a systematic literature review. <i>Rheumatology</i> , 2015 , 54, 981-93	3.9	15
217	Work outcome in persons with musculoskeletal diseases: comparison with other chronic diseases & the role of musculoskeletal diseases in multimorbidity. <i>BMC Musculoskeletal Disorders</i> , 2017 , 18, 10	2.8	14

216	Patients' preferences and economic considerations play an important role in treatment decisions: a discrete choice experiment among rheumatologists. <i>Rheumatology</i> , 2017 , 56, 68-76	3.9	14
215	The OMERACT Core Domain Set for Clinical Trials of Shoulder Disorders. <i>Journal of Rheumatology</i> , 2019 , 46, 969-975	4.1	14
214	Differences and similarities in rheumatology specialty training programmes across European countries. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1183-7	2.4	14
213	Large country differences in work outcomes in patients with RA - an analysis in the multinational study COMORA. <i>Arthritis Research and Therapy</i> , 2017 , 19, 216	5.7	14
212	Rheumatology training experience across Europe: analysis of core competences. <i>Arthritis Research and Therapy</i> , 2016 , 18, 213	5.7	14
211	A psychometric analysis of outcome measures in peripheral spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1302-7	2.4	14
210	Treat to Target in Rheumatology: A Historical Account on Occasion of the 10th Anniversary. <i>Rheumatic Disease Clinics of North America</i> , 2019 , 45, 477-485	2.4	14
209	Brief report: erosions and sclerosis on radiographs precede the subsequent development of syndesmophytes at the same site: a twelve-year prospective followup of patients with ankylosing spondylitis. <i>Arthritis and Rheumatology</i> , 2014 , 66, 2773-9	9.5	14
208	Impact of socioeconomic gradients within and between countries on health of patients with rheumatoid arthritis (RA): lessons from QUEST RA. <i>Best Practice and Research in Clinical Rheumatology</i> , 2012 , 26, 705-20	5.3	14
207	Hemocytometric characteristics of COVID-19 patients with and without cytokine storm syndrome on the sysmex XN-10 hematology analyzer. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021 , 59, 783-793 ^{5.9}	5.9	14
206	Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. <i>Lupus Science and Medicine</i> , 2020 , 7,	4.6	14
205	Inequity in biological DMARD prescription for spondyloarthritis across the globe: results from the ASAS-COMOSPA study. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 405-411	2.4	14
204	Three handy tips and a practical guide to improve your propensity score models. <i>RMD Open</i> , 2019 , 5, e000953	5.9	13
203	Hierarchy of Impairment of Spinal Mobility Measures in Ankylosing Spondylitis: Twelve-Year Data. <i>Arthritis Care and Research</i> , 2015 , 67, 1571-7	4.7	13
202	Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial. <i>RMD Open</i> , 2019 , 5, e001040	5.9	13
201	Is it Useful to Repeat Magnetic Resonance Imaging of the Sacroiliac Joints After Three Months or One Year in the Diagnosis of Patients With Chronic Back Pain and Suspected Axial Spondyloarthritis?. <i>Arthritis and Rheumatology</i> , 2019 , 71, 382-391	9.5	13
200	The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2019 , 21, 164	5.7	12
199	Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA. <i>Current Medical Research and Opinion</i> , 2011 , 27, 315-25	2.5	12

198	Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 276-284	5.3	12
197	EpiReumaPt Protocol - Portuguese epidemiologic study of the rheumatic diseases. <i>Acta Reumatologica Portuguesa</i> , 2010 , 35, 384-90	0.7	12
196	Individual-level and country-level socioeconomic determinants of disease outcomes in SpA: multinational, cross-sectional study (ASAS-COMOSPA). <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 486-493	2.4	11
195	Work participation in spondyloarthritis across countries: analysis from the ASAS-COMOSPA study. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1303-1310	2.4	11
194	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 872-878	2.4	11
193	Are serum autoantibodies associated with brain changes in systemic lupus erythematosus? MRI data from the Leiden NP-SLE cohort. <i>Lupus</i> , 2019 , 28, 94-103	2.6	11
192	Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1755-60	2.4	10
191	OP0095 Randomized, Placebo-Controlled Trial To Evaluate Clinical Efficacy and Structure Modifying Properties of Subcutaneous Etanercept (ETN) in Patients with Erosive Inflammatory Hand Osteoarthritis (OA). <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 90.3-91	2.4	10
190	Fluctuations in patient reported disease activity, pain and global being in patients with ankylosing spondylitis. <i>Rheumatology</i> , 2016 , 55, 2014-2022	3.9	10
189	Impact of flare on radiographic progression after etanercept continuation, tapering or withdrawal in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2020 , 59, 153-164	3.9	10
188	Do extra-articular manifestations influence outcome in ankylosing spondylitis? 12-year results from OASIS. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, 214-21	2.2	10
187	Defining remission and treatment success using the DAPSA score: response to letter by Helliwell and Coates. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, e67	2.4	9
186	Chronicity of rheumatoid arthritis affects the responsiveness of physical function, but not of disease activity measures in rheumatoid arthritis clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 532-7	2.4	9
185	Combination therapy for pain management in inflammatory arthritis: a Cochrane systematic review. <i>Journal of rheumatology Supplement, The</i> , 2012 , 90, 47-55		9
184	RAPID and FAST4WARD trials: certolizumab pegol for rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2010 , 6, 713-20	5.1	9
183	Diagnostic use of office-based ultrasound. Baker's cyst of the right knee joint. <i>Arthritis and Rheumatism</i> , 1995 , 38, 859-61		9
182	Comparing the Patient-Reported Physical Function Outcome Measures in a Real-Life International Cohort of Patients With Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2021 , 73, 593-602	4.7	9
181	Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 709-718	5.3	8

180	Tumor Necrosis Factor Inhibitors Reduce Spinal Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: A Longitudinal Analysis From the Alberta Prospective Cohort. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1211-1219	9.5	8
179	Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial. <i>Rheumatology</i> , 2021 , 60, 256-262	3.9	8
178	Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider. <i>RMD Open</i> , 2018 , 4, e000756	5.9	8
177	EULAR 'points to consider' for the conduction of workforce requirement studies in rheumatology. <i>RMD Open</i> , 2018 , 4, e000780	5.9	8
176	Disease activity assessment in patients with psoriatic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018 , 32, 401-414	5.3	8
175	Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative. <i>Journal of Rheumatology</i> , 2019 , 46, 1159-1163	4.1	7
174	Improving the peer review skills of young rheumatologists and researchers in rheumatology: the EMEUNET Peer Review Mentoring Program. <i>RMD Open</i> , 2018 , 4, e000619	5.9	7
173	Educational needs and preferences of young European clinicians and physician researchers working in the field of rheumatology. <i>RMD Open</i> , 2016 , 2, e000240	5.9	7
172	Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis. <i>RMD Open</i> , 2018 , 4, e000602	5.9	7
171	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	7
170	Assessment of competences in rheumatology training: results of a systematic literature review to inform EULAR points to consider. <i>RMD Open</i> , 2020 , 6,	5.9	7
169	Work Disability in Axial Spondyloarthritis. <i>Current Rheumatology Reports</i> , 2020 , 22, 55	4.9	7
168	Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant?. <i>Arthritis Research and Therapy</i> , 2020 , 22, 195	5.7	7
167	Is active sacroiliitis on MRI associated with radiographic damage in axial spondyloarthritis? Real-life data from the ASAS and DESIR cohorts. <i>Rheumatology</i> , 2019 , 58, 798-802	3.9	7
166	Adherence to Treat-to-target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort. <i>Journal of Rheumatology</i> , 2020 , 47, 809-819	4.1	7
165	Uncovering the heterogeneity of disease impact in axial spondyloarthritis: bivariate trajectories of disease activity and quality of life. <i>RMD Open</i> , 2018 , 4, e000755	5.9	7
164	Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study. <i>RMD Open</i> , 2018 , 4, e000766	5.9	7
163	Frequency of Impaired Spinal Mobility in Patients with Chronic Back Pain Compared to Patients with Early Axial Spondyloarthritis. <i>Journal of Rheumatology</i> , 2018 , 45, 1643-1650	4.1	7

162	Percentage of progressors in imaging: can we ignore regressors?. <i>RMD Open</i> , 2019 , 5, e000848	5.9	6
161	Measuring spinal mobility in early axial spondyloarthritis: does it matter?. <i>Rheumatology</i> , 2019 , 58, 1597-1606	6.0	6
160	Comparison of tests for lumbar flexion and hip function in patients with and without axial spondyloarthritis. <i>Arthritis Care and Research</i> , 2015 , 67, 538-45	4.7	6
159	5-year follow-up of spinal and sacroiliac MRI abnormalities in early axial spondyloarthritis: data from the DESIR cohort. <i>RMD Open</i> , 2020 , 6,	5.9	6
158	SAT0575 Disease Activity in Psoriatic Arthritis (PSA): Defining Remission and Treatment Success Using the Dapsa-Score. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 869.1-869	2.4	6
157	How do gastrointestinal or liver comorbidities influence the choice of pain treatment in inflammatory arthritis? A Cochrane systematic review. <i>Journal of rheumatology Supplement, The</i> , 2012 , 90, 74-80		6
156	Association of the different types of radiographic damage with physical function in patients with rheumatoid arthritis: analysis of the RAPID trials. <i>RMD Open</i> , 2016 , 2, e000219	5.9	6
155	The ASAS-OMERACT core domain set for axial spondyloarthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2021 ,	5.3	6
154	Do Smoking and Socioeconomic Factors Influence Imaging Outcomes in Axial Spondyloarthritis? Five-Year Data From the DESIR Cohort. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1855-1862	9.5	5
153	Empty Capsids and Macrophage Inhibition/Depletion Increase rAAV Transgene Expression in Joints of Both Healthy and Arthritic Mice. <i>Human Gene Therapy</i> , 2017 , 28, 168-178	4.8	5
152	An updated matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases. <i>Rheumatology</i> , 2020 , 59, 1842-1852	3.9	5
151	Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19- associated cytokine storm syndrome: results of the CHIC study' by Calvo-Aranda. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	5
150	COVID-19-induced hyperinflammation, immunosuppression, recovery and survival: how causal inference may help draw robust conclusions. <i>RMD Open</i> , 2021 , 7,	5.9	5
149	Determinants of sleep impairment in psoriatic arthritis: An observational study with 396 patients from 14 countries. <i>Joint Bone Spine</i> , 2020 , 87, 449-454	2.9	5
148	Development and validation of an alternative ankylosing spondylitis disease activity score when patient global assessment is unavailable. <i>Rheumatology</i> , 2021 , 60, 638-648	3.9	5
147	Addressing Health Literacy Needs in Rheumatology: Which Patient Health Literacy Profiles Need the Attention of Health Professionals?. <i>Arthritis Care and Research</i> , 2021 , 73, 100-109	4.7	5
146	Disease activity is associated with spinal radiographic progression in axial spondyloarthritis independently of exposure to tumour necrosis factor inhibitors. <i>Rheumatology</i> , 2021 , 60, 461-462	3.9	5
145	Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study. <i>RMD Open</i> , 2018 , 4, e000773	5.9	5

144	Which scoring method depicts spinal radiographic damage in early axial spondyloarthritis best? Five-year results from the DESIR cohort. <i>Rheumatology</i> , 2018 , 57, 1991-2000	3.9	5
143	Response to: '2016 update of the EULAR recommendations for the management of rheumatoid arthritis: no utopia for patients in low/middle-income countries?' by Misra. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, e48	2.4	4
142	Early response to therapy predicts 6-month and 1-year disease activity outcomes in psoriatic arthritis patients. <i>Rheumatology</i> , 2018 , 57, 969-976	3.9	4
141	How to deal with missing items in BASDAI and BASFI. <i>Rheumatology</i> , 2014 , 53, 374-6	3.9	4
140	Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study. <i>Rheumatology and Therapy</i> , 2020 , 7, 1021-1033	4.4	4
139	Strategies for the assessment of competences during rheumatology training across Europe: results of a qualitative study. <i>RMD Open</i> , 2020 , 6,	5.9	4
138	Multidisciplinary collaboration among young specialists: results of an international survey by the emerging EULAR network and other young organisations. <i>RMD Open</i> , 2020 , 6,	5.9	4
137	Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI. <i>RMD Open</i> , 2020 , 6,	5.9	4
136	Young people's perspectives on patient-reported outcome measures in inflammatory arthritis: results of a multicentre European qualitative study from a EULAR task force. <i>RMD Open</i> , 2021 , 7,	5.9	4
135	CoReumaPt protocol: the Portuguese cohort of rheumatic diseases. <i>Acta Reumatologica Portuguesa</i> , 2012 , 37, 18-24	0.7	4
134	Reference curves for the Australian/Canadian Hand Osteoarthritis Index in the middle-aged Dutch population. <i>Rheumatology</i> , 2017 , 56, 745-752	3.9	3
133	Person-focused care for young people with rheumatic and musculoskeletal diseases: young rheumatologists' and EULAR Young PARE perspectives. <i>RMD Open</i> , 2017 , 3, e000514	5.9	3
132	What Do the OMERACT Shoulder Core Set Candidate Instruments Measure? An Analysis Using the Refined International Classification of Functioning, Disability, and Health Linking Rules. <i>Journal of Rheumatology</i> , 2020 , 47, 1557-1564	4.1	3
131	Deriving common comorbidity indices from the MedDRA classification and exploring their performance on key outcomes in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2018 , 57, 548-554	3.9	3
130	Equivalence in the Health Assessment Questionnaire (HAQ) across socio-demographic determinants: Analyses within QUEST-RA. <i>Seminars in Arthritis and Rheumatism</i> , 2018 , 47, 492-500	5.3	3
129	To DAPSA or not to DAPSA? That is not the question. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e61	2.4	3
128	Measures of Adult Shoulder Function. <i>Arthritis Care and Research</i> , 2020 , 72 Suppl 10, 250-293	4.7	3
127	EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1423-1431	2.4	3

126	Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects. <i>RMD Open</i> , 2021 , 7,	5.9	3
125	Biological DMARDs and disease modification in axial spondyloarthritis: a review through the lens of causal inference. <i>RMD Open</i> , 2021 , 7,	5.9	3
124	Performance of referral strategies for spondyloarthritis: a population-based nationwide study. <i>Rheumatology</i> , 2019 , 58, 1086-1094	3.9	3
123	Targeting IL-6: A review of data 2018 , 2, 12-18		3
122	Is radiographic progression in radiographic axial spondyloarthritis related to matrix metalloproteinase degradation of extracellular matrix?. <i>RMD Open</i> , 2018 , 4, e000648	5.9	3
121	Influence of disease activity on RA treatment choices in countries with restricted access to expensive, innovative drugs: a discrete choice experiment among rheumatologists. <i>RMD Open</i> , 2017 , 3, e000453	5.9	2
120	OP0031 A Phase 2 Study Evaluating the Efficacy and Safety of Subcutaneously Administered Ustekinumab and Guselkumab in Patients with Active Rheumatoid Arthritis Despite Treatment with Methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 76.2-77	2.4	2
119	Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 643-644	5.3	2
118	Integrated longitudinal analysis does not compromise precision and reduces bias in the study of imaging outcomes: A comparative 5-year analysis in the DESIR cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 1394-1399	5.3	2
117	In patients with axial spondyloarthritis, inflammation on MRI of the spine is longitudinally related to disease activity only in men: 2 years of the axial spondyloarthritis DESIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 470-472	2.4	2
116	Response to: 'Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update' by Goswami et al. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, e36	2.4	2
115	Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1472-1479	2.4	2
114	Neutral lateral fingertip-to-floor distance can be derived from height. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1748-9	2.4	2
113	AB0380 Treat-to-target in systemic lupus erythematosus: report from the t2t/sle working party. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A903.2-A903	2.4	2
112	Development of amyloidosis in patients with rheumatoid arthritis under TNF-blocking agents. <i>Clinical Rheumatology</i> , 2011 , 30, 869-70	3.9	2
111	Analysis of TNFR2-mediated functions on osteoclast precursor cells. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, A35-A36	2.4	2
110	FRI0553 Back to being normal—the patient perspective on remission in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A562.2-A562	2.4	2
109	Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2020 , 22, 188	5.7	2

108	Response to: 'High dosage of Methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to Tocilizumab' by Conticini. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	2
107	EULAR Points to Consider (PtC) for designing, analysing and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1116-1123	2.4	2
106	2019 EULAR points to consider for the assessment of competences in rheumatology specialty training. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 65-70	2.4	2
105	Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by Charles. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	2
104	Considering new lessons about the use of IL-6 inhibitors in arthritis 2018 , 2, 7-11		2
103	Considerations and priorities for incorporating the patient perspective on remission in rheumatoid arthritis: An OMERACT 2020 special interest group report. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 1108-1112	5.3	2
102	Portuguese recommendations for the use of biological therapies in patients with axial spondyloarthritis - 2016 update. <i>Acta Reumatologica Portuguesa</i> , 2017 , 42, 209-218	0.7	2
101	Socio-economic inequalities in occurrence and health care costs in rheumatic and musculoskeletal diseases: results from a Spanish population-based study including 1.9 million persons. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36, 589-594	2.2	2
100	Mentoring for postdoctoral researchers in rheumatology: the Emerging EULAR Network (EMEUNET) post-doc mentoring programme. <i>RMD Open</i> , 2020 , 6,	5.9	1
99	Response to: 'Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis' by Bugatti. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	1
98	Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis. <i>RMD Open</i> , 2020 , 6,	5.9	1
97	Outcomes and Findings of the International Rheumatoid Arthritis (RA) BIODAM Cohort for Validation of Soluble Biomarkers in RA. <i>Journal of Rheumatology</i> , 2020 , 47, 796-808	4.1	1
96	Is Methotrexate as Efficacious as Etanercept in Psoriatic Arthritis Patients? Comment on the Article by Mease et al. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1227-1229	9.5	1
95	THU0031 Baseline Characteristics and Treatment Outcomes of Patients Who Achieve Deep Remission in Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 188.2-189	2.4	1
94	Does Triple Conventional Synthetic Disease-Modifying Antirheumatic Drug Therapy Improve upon Methotrexate as the Initial Treatment of Choice for a Rheumatoid Arthritis Patient?. <i>Rheumatic Disease Clinics of North America</i> , 2019 , 45, 315-324	2.4	1
93	FRI0047 The Patient Perspective on Absence of Disease Activity in Rheumatoid Arthritis: A Survey to Identify Key Domains of Patient Perceived Remission. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 435.3-436 ¹	2.4	1
92	AB0075 MTOR: An Unexpected Role on the TNF-Regulated mRNA Transcriptome in Rheumatoid Fibroblast-Like Synoviocytes. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 915.3-916	2.4	1
91	THU0282 Immunoabsorption in Lupus Nephritis: Three Different High Affinity Columns are Equally Effective in Inducing Remission. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A261.2-A261	2.4	1

90	On publication policy, combination therapy, and the European League Against Rheumatism recommendations for the management of rheumatoid arthritis: comment on the article by Graudal et al. <i>Arthritis and Rheumatism</i> , 2011 , 63, 3182-4; discussion 3184-6		1
89	THU0586 ESTABLISHING THE KEY COMPONENTS OF A EULAR PORTFOLIO FOR TRAINING IN RHEUMATOLOGY: A EULAR SCHOOL OF RHEUMATOLOGY INITIATIVE. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 535.1-535	2.4	1
88	Which imaging outcomes for axSpA are most sensitive to change? A 5-Year analysis of The DESIR Cohort. <i>Arthritis Care and Research</i> , 2020 ,	4.7	1
87	Response to 'Neither earlier not late tocilizumab improved outcomes in the intensive care unit patients with COVID-19 in a retrospective cohort study' by Moiseev. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	1
86	Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by Charles. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	1
85	Peripheral arthritis and higher disease activity lead to more functional impairment in axial spondyloarthritis: Longitudinal analysis from ESPAXIA. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 553-558	5.3	1
84	Endorsement of the domains of knee and hip osteoarthritis (OA) flare: A report from the OMERACT 2020 inaugural virtual consensus vote from the flares in OA working group. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 618-622	5.3	1
83	FRI0393 Cut-Off Values for Intima-Media Thickness of Temporal, Facial and Axillary Arteries in Giant Cell Arteritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 577.1-577	2.4	1
82	Response to: 'The role of temporal artery biopsy in patients with giant cell arteritis is debated' by Moiseev. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e32	2.4	1
81	Determinants of the patient global assessment of well-being in early axial spondyloarthritis: 5-year longitudinal data from the DESIR cohort. <i>Rheumatology</i> , 2021 , 60, 316-321	3.9	1
80	Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by De Santis. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	1
79	Methodological aspects of design, analysis and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis: results of two systematic literature reviews informing EULAR points to consider. <i>RMD Open</i> , 2021 , 7,	5.9	1
78	Socio-economic gradients in the presence of musculoskeletal and other chronic diseases: results from a cross-sectional study in the Netherlands. <i>Clinical Rheumatology</i> , 2018 , 37, 3173-3182	3.9	1
77	Association between individual and country-level socioeconomic factors and work participation in spondyloarthritis including psoriatic arthritis: Analysis of the ASAS-perSpA study. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 804-812	5.3	1
76	Translation and cross-cultural adaptation of the ASAS Health Index and ASAS Environmental Factors Item Set into European Portuguese Language. <i>Acta Reumatologica Portuguesa</i> , 2017 , 42, 256-262	0.7	1
75	Response to: 'Concerns on glucocorticoid use for Japanese patients with established rheumatoid arthritis' by Oiwa. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, e36	2.4	0
74	FRI0090 Fulfilling only three of four ACR/EULAR boolean remission criteria is not predictive of subsequent full remission. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 339.3-340	2.4	0
73	Response to: Where are the women 'Heroes and Pillars of Rheumatology'?. <i>Annals of the Rheumatic Diseases</i> , 2022 ,	2.4	0

72	Which disease activity outcome measure discriminates best in axial spondyloarthritis? A systematic literature review and meta-analysis. <i>Rheumatology</i> , 2020 , 59, 3990-3992	3.9	○
71	Greetings from the editor. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 677-678	2.4	○
70	Antibody response to SARS-CoV-2 in patients receiving glucocorticoids with or without tocilizumab for COVID-19-associated hyperinflammation. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1362-1363	2.4	○
69	Comment on: Development and validation of an alternative ankylosing spondylitis disease activity score when patient global assessment is unavailable: reply. <i>Rheumatology</i> , 2021 , 60, e71-e72	3.9	○
68	What influences patients' opinion of remission and low disease activity in psoriatic arthritis? Principal component analysis of an international study. <i>Rheumatology</i> , 2021 , 60, 5292-5299	3.9	○
67	Evolving the comprehensive management of rheumatoid arthritis: identification of unmet needs and development of practical and educational tools. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38, 1056-1067	2.2	○
66	Response to: 'The time has come to revisit alternative interpretations of data underlying the EULAR management recommendations for rheumatoid arthritis' by Pirić <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, e50	2.4	
65	OP0185 Significant Clinical Improvement and Reduction of Severe Flares Following Administration of an IL-6 Monoclonal Antibody in Systemic Lupus Erythematosus (SLE) Subjects with High Disease Activity. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 141.2-142	2.4	
64	SAT0050 Resident Non-Classical Monocytes Are Critically Important for Tissue Destruction in Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 681.3-682	2.4	
63	SAT0525 The Use of Analgesic and Other Pain Relief Drugs To Manage Chronic Low Back Pain □ Results from A National Survey. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 859.2-859	2.4	
62	FRI0582 Fluctuating Levels of Rheumatoid Factor Predict Progression of Rheumatoid Arthritis, but Not Independent of Disease Activity. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 652.2-653	2.4	
61	AB0136 In Vitro Induced Regulatory T-Cells Can Reduce Severity of Lupus Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 943.2-943	2.4	
60	THU0598 Variations in Policies and Social Security Regulations for Patients with Rheumatoid Arthritis That Experience Restrictions in Work Participation: Results from A Survey across 44 Countries of The European Region. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 408.2-408	2.4	
59	THU0628 Socio-Economically Deprived Patients Have A Higher Likelihood for Having Any Type of Rheumatic and Musculoskeletal Diseases and Have Higher Healthcare Costs - Results from A Population-Based Administrative Database Including 1.9 Million Persons (Basque Country, Spain). <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 409.2-409	2.4	
58	THU0148 Economic Considerations and Patients' Preferences Affect Treatment Selection for Rheumatoid Arthritis Patients: A Discrete Choice Experiment among European Rheumatologists. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 235.2-235	2.4	
57	OP0298 The Role of CD11c+ Dendritic Cells in Inflammatory Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 174.4-175	2.4	
56	AB0178 Characterization of CD4+ T Cell Response and Effects of Regulatory T Cells in Pristane Induced Lupus (PIL). <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 861.4-862	2.4	
55	AB0273 Personal Factors Important to People with Rheumatoid Arthritis and their Coverage by Patient-Reported Outcome Measures. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 894.3-894	2.4	

54	A1.24 Cilengitide reduces pannus formation and bone erosions in collagen induced arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, A10.1-A10	2.4
53	SAT0238 Gender-Attributable Differences in Outcome of Ankylosing Spondylitis: Long-Term Results from the Outcome in Ankylosing Spondylitis International Study. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 744.2-745	2.4
52	SAT0637-HPR Impairment in the Activities of Daily Living in Older Adults with and Without Osteoporosis, Osteoarthritis and Chronic Back Pain: Results of a Population-Based Cross-Sectional Study. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1334.2-1334	2.4
51	SAT0566 Impact of Disease Management by Rheumatologists and Dermatologists on Patients' Attitude Toward Medication in Psoriatic Arthritis: Results from the Global Align Study. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 865.2-866	2.4
50	FRI0234 Spinal Radiographic Progression in Early Axial Spondyloarthritis: Data from the Desir Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 509.2-509	2.4
49	AB0790 Which Score to Use for Radiographic Damage Assessment of the Spine in (Early) Axial Spondyloarthritis? Two-Year Data From the Desir Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1163.2-1163	2.4
48	THU0103 Differences in Patients with Rheumatoid Arthritis who Achieved DAS Remission or SDAI Remission but not Boolean Remission. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 230.1-230	2.4
47	SAT0356 Predictive Utility of Anti-Citrullinated Peptide Antibodies and Rheumatoid Factor $\bar{\alpha}$ Retrospective Data Analysis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 788.1-788	2.4
46	Response to 'dual training in general internal medicine and rheumatology: the Irish context' by Dr Sheane. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, e56	2.4
45	SAT0053 Persistence of Subclinical Joint Activity in Rheumatoid Arthritis Joints. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 608.2-608	2.4
44	OP0284 Mtor Plays A Decisive Role in the Rheumatoid Mesenchymal Tissue Response to Inflammation. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 169.2-169	2.4
43	THU0479 Dheas-Associated Genotypes Contribute to Adrenal Androgen Hypofunction in RA. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 349.1-349	2.4
42	A1.80 Alterations in gait profile and bone marrow inflammation before the onset of collagen-induced arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, A35.2-A35	2.4
41	AB0127 Arthritis in a model for systemic lupus: involvement of joints, inner organs and course of autoantibodies in pristane-induced lupus.. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A824.2-A824	2.4
40	SAT0057 Functional impairment in an animal model for rheumatoid arthritis assessed as changes in gait is due to joint destruction but not synovial inflammation per SE. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 489.2-489	2.4
39	A9.9 Treatment with BGP-15, a Novel Insulin Sensitiser Attenuates Collagen-Induced Arthritis in DBA/1 Mice. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A67.2-A68	2.4
38	AB0174 Muscle wasting in HTNFTG mice; an animal model for rheumatoid arthritis; due to increased cathepsin l expression. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 647.11-647	2.4
37	OP0201-HPR Development of user- focused standards of care for rheumatoid arthritis the www.eumusc.net project - work package 5. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 123.1-123	2.4

- 36 FRI0432 Comparison of tests for lumbar flexion and hip function in patients with axial spondyloarthritis and in healthy controls. *Annals of the Rheumatic Diseases*, **2013**, 72, A521.1-A521 2.4
- 35 THU0018 Discrimination Analysis of Multiple Genetic Risk Markers Associated with Rheumatoid Arthritis in Slovakia. *Annals of the Rheumatic Diseases*, **2013**, 72, A170.2-A170 2.4
- 34 THU0559 Patient Education, Disease Activity and Physical Function. Can we be more Targeting? A Cross Sectional Study among People with RA, PsA and Hand OA. *Annals of the Rheumatic Diseases*, **2013**, 72, A353.2-A353 2.4
- 33 FRI0082 Radiographic progression in rheumatoid arthritis in the 21st century. *Annals of the Rheumatic Diseases*, **2013**, 72, A396.3-A397 2.4
- 32 AB0185 Clinical joint involvement is decisive for radiographic progression. *Annals of the Rheumatic Diseases*, **2013**, 72, A842.2-A842 2.4
- 31 SAT0030 Quality Indicators (QIS) in Rheumatoid Arthritis (RA) in Clinical Practice: Results from Measurement of Efficacy of Treatment in The ERA of Outcome in Rheumatology (Meteor) Database. *Annals of the Rheumatic Diseases*, **2013**, 72, A589.3-A590 2.4
- 30 FRI0270 Development of systemic lupus-like disease in regulatory T cells (TREG)-deficient scurfy mice.. *Annals of the Rheumatic Diseases*, **2013**, 72, A465.3-A466 2.4
- 29 THU0094 Treatment with BGP-15, a Novel Insulin Sensitizer Attenuates Collagen-Induced Arthritis in DBA/1 Mice. *Annals of the Rheumatic Diseases*, **2013**, 72, A194.3-A195 2.4
- 28 FRI0488-HPR Are occupational therapy interventions included in the most commonly used european clinical-practice guidelines for the management of osteoarthritis?. *Annals of the Rheumatic Diseases*, **2013**, 71, 754.1-754 2.4
- 27 Interleukin-6 is not a crucial regulator in tumour necrosis factor-mediated bilateral sacroiliitis. *Annals of the Rheumatic Diseases*, **2010**, 69, A49-A50 2.4
- 26 Apoptosis and the subsequent generation of autoantigens as initial triggers in the pathogenesis of experimental autoimmune arthritis. *Annals of the Rheumatic Diseases*, **2010**, 69, A60-A60 2.4
- 25 Class effects of tyrosine kinase inhibitors on osteoclastogenesis in vitro. *Annals of the Rheumatic Diseases*, **2011**, 70, A80-A80 2.4
- 24 THU0583 STRATEGIES FOR ASSESSMENT OF COMPETENCES DURING RHEUMATOLOGY TRAINING ACROSS EUROPE: RESULTS OF A QUALITATIVE STUDY.. *Annals of the Rheumatic Diseases*, **2020**, 79, 533.1-534 2.4
- 23 OP0315 WHICH RESPONSE OR STATUS CRITERION DISCRIMINATES BEST IN AXSPA?. *Annals of the Rheumatic Diseases*, **2020**, 79, 194.1-195 2.4
- 22 Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by Kaklamanos. *Annals of the Rheumatic Diseases*, **2021**, 2.4
- 21 Les dÉterminants des troubles du sommeil dans le rhumatisme psoriasique : Étude observationnelle portant sur 696 patients de 14 pays. *Revue Du Rhumatisme (Edition Francaise)*, **2021**, 88, 201-207 0.1
- 20 POS0953 PERIPHERAL ARTHRITIS AND HIGHER DISEASE ACTIVITY LEAD TO MORE FUNCTIONAL IMPAIRMENT IN AXIAL SPONDYLOARTHRITIS: LONGITUDINAL ANALYSIS FROM ESPAXIA. *Annals of the Rheumatic Diseases*, **2021**, 80, 740.2-741 2.4
- 19 POS0924 PREDICTORS OF 1-YEAR TREATMENT RESPONSE AMONG UPADACITINIB-TREATED PATIENTS WITH ANKYLOSING SPONDYLITIS: A POST HOC ANALYSIS OF SELECT-AXIS 1. *Annals of the Rheumatic Diseases*, **2021**, 80, 723-724 2.4

18	POS0299 SOCIOECONOMIC BACKGROUND IS ASSOCIATED WITH DISCORDANCE BETWEEN HEALTH LITERACY OF PEOPLE WITH RMDs AND ASSESSMENT OF HEALTH LITERACY BY THEIR TREATING HEALTH PROFESSIONAL. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 374.2-375	2.4
17	POS0181 HOW FIT ARE THE SOCIAL SUPPORT INSTRUMENTS USED IN RMDs: A SYSTEMATIC REVIEW OF VALIDATION STUDIES. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 304.1-304	2.4
16	OP0250 MRI VERTEBRAL CORNER INFLAMMATION AND FAT DEPOSITION ARE ASSOCIATED WITH WHOLE SPINE LOW DOSE CT DETECTED SYNDESMOPHYTES: A MULTILEVEL ANALYSIS. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 152.1-153	2.4
15	Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19- associated cytokine storm syndrome: results of the CHIC study'' by Klopfenstein. <i>Annals of the Rheumatic Diseases</i> , 2021	2.4
14	THU0041 Large Country Differences in Work Outcomes in Patients with RA [An Analysis in The Multinational Study Comora. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 192.2-192	2.4
13	THU0403 Performance of Modified Minimal Disease Activity (MDA) Criteria in Patients with Peripheral Spondyloarthritis: Post-Hoc Analysis of Ability-2. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 334.1-334	2.4
12	FRI0133 Understanding Anemia in Rheumatoid Arthritis: The Association of Hemoglobin and Hepcidin Levels with Clinical Disease Activity and Acute Phase Response. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 476.1-476	2.4
11	AB0135 Decreased Lupus Manifestations in Pristane-Induced Microrna 155-Deficient Mice. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 943.1-943	2.4
10	FRI0585 Importance and Level of Implementation of The EULAR/EUMUSC.net Standards of Care for RA in The Netherlands: Similarities and Discordance between Patients and Health Care Professionals. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 653.3-654	2.4
9	SAT0446 Reference Curves for The Australian/canadian Hand Osteoarthritis Index (AUSCAN) in The General Population. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 833.1-833	2.4
8	SAT0081 The Diagnostic and Predictive Value of Anti-Acetylated Peptide Antibodies (AAPA) in Rheumatoid Arthritis Patients Starting Their First Dmard Treatment on Methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 694.1-694	2.4
7	Response to: 'Reactive arthritis, a missing link: comment on the recent article from Sepriano ' by Zeidler and Hudson. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4
6	Response to: 'The GRAPPA-OMERACT initiative to standardise outcomes in Psoriatic Arthritis clinical trials and longitudinal observational studies' by Tillet. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, e24	2.4
5	IL-6: To immunity and beyond 2018 , 2, 19-23	
4	Biologicals and switch in rheumatoid arthritis throughout time - are we being more aggressive?. <i>Acta Reumatologica Portuguesa</i> , 2011 , 36, 234-42	0.7
3	Obesity and diabetes are associated with disability in women with hand osteoarthritis. Results from the EpiReumaPt nationwide study. <i>Acta Reumatologica Portuguesa</i> , 2021 , 46, 208-217	0.7
2	Muscle dysfunction in axial spondylarthritis: the MyoSpA study. <i>Clinical and Experimental Rheumatology</i> , 2022 , 40, 267-273	2.2
1	The role of muscle in the susceptibility and progression of axial Spondyloarthritis: The MyoSpA Study Protocol.. <i>Acta Reumatologica Portuguesa</i> , 2021 , 46, 342-349	0.7

